Fidelity Investments
UBX

Fidelity Investments’s Unity Biotechnology UBX Stock Holding History

Fidelity Investments’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$2 – 5509
2025
Q1 		$2 Buy
+2
New +$4 ﹤0.01% 5271
2024
Q4 		– Sell
-10
Closed -$15 – 5815
2024
Q3 		$15 Buy
+10
New +$15 ﹤0.01% 5392
2024
Q2 		– Sell
-10
Closed -$16 – 5644
2024
Q1 		$16 Sell
10
-27
-73% -$47 ﹤0.01% 5223
2023
Q4 		$71 Sell
37
-53
-59% -$99 ﹤0.01% 4974
2023
Q3 		$216 Buy
90
+84
+1,400% +$223 ﹤0.01% 4783
2023
Q2 		$15 Sell
6
-287,981
-100% -$761K ﹤0.01% 5226
2023
Q1 		$469K Sell
287,987
-475,133
-62% -$1.9M ﹤0.01% 2708
2022
Q4 		$2.09M Buy
763,120
+8,798
+1% +$25.6K ﹤0.01% 2363
2022
Q3 		$2.98M Buy
754,322
+660,921
+708% +$4.17M ﹤0.01% 2317
2022
Q2 		$527K Sell
93,401
-120,691
-56% -$1.01M ﹤0.01% 2830
2022
Q1 		$2.4M Sell
214,092
-96,561
-31% -$1.08M ﹤0.01% 2555
2021
Q4 		$4.54M Sell
310,653
-46,979
-13% -$1.03M ﹤0.01% 2390
2021
Q3 		$10.7M Sell
357,632
-45,600
-11% -$1.61M ﹤0.01% 2103
2021
Q2 		$18.7M Sell
403,232
-8,280
-2% -$399K ﹤0.01% 1870
2021
Q1 		$24.7M Sell
411,512
-46,850
-10% -$3.19M ﹤0.01% 1716
2020
Q4 		$24M Sell
458,362
-26,880
-6% -$1.3M ﹤0.01% 1630
2020
Q3 		$16.8M Sell
485,242
-124,640
-20% -$7.89M ﹤0.01% 1635
2020
Q2 		$52.9M Buy
609,882
+34,833
+6% +$2.58M 0.01% 1136
2020
Q1 		$33.4M Buy
575,049
+89,950
+19% +$5.67M ﹤0.01% 1190
2019
Q4 		$35M Buy
485,099
+20,780
+4% +$1.47M ﹤0.01% 1372
2019
Q3 		$28.3M Sell
464,319
-6,427
-1% -$455K ﹤0.01% 1437
2019
Q2 		$44.7M Buy
470,746
+15,594
+3% +$1.33M 0.01% 1276
2019
Q1 		$36.9M Buy
455,152
+70,050
+18% +$7.94M ﹤0.01% 1348
2018
Q4 		$62.6M Buy
385,102
+28,830
+8% +$3.83M 0.01% 1057
2018
Q3 		$56.2M Buy
356,272
+8,651
+2% +$1.42M 0.01% 1214
2018
Q2 		$49M Buy
+347,621
New +$50.8M 0.01% 1284

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments's UBX Position: Q2 2025 in Review

Fidelity Investments sold out of Unity Biotechnology (UBX) in Q2 2025, closing a stake of 2 shares — an estimated $2 sold.

Fidelity Investments first reported a position in UBX in Q2 2018 and held it in 26 quarters. The position peaked at $62.6M in Q4 2018. 35 funds tracked by Wall St. Rank hold UBX as of Q2 2025.

  • Fidelity Investments reported no remaining Unity Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Fidelity Investments sold 2 Unity Biotechnology shares in Q2 2025, an estimated $2.
  • Fidelity Investments first reported a position in Unity Biotechnology in Q2 2018 and held it in 26 quarters.
  • Fidelity Investments's Unity Biotechnology position peaked at $62.6M in Q4 2018.
  • 35 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2025.

Based on Fidelity Investments's 13F filing for Q2 2025, filed 14 Aug 2025.